Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update


During the third quarter, Wave Life Sciences maintained strong momentum in advancing our three clinical programs and expect to announce our companys first clinical readout later this year when we share topline safety results from the Phase 1 trial for WVE-210201, our investigational exon 51 skipping candidate for the treatment of Duchenne muscular dystrophy, said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. Beyond our ongoing clinical programs, we spent much of the last quarter focused on expanding our discovery efforts into inherited retinal …

[Read on via official release]

Source: US SEC
View full document: EX-991_of_8-K_for_Wave_Life_Sciences_Ltd__8-K-11-09-2018